Solanezumab and the amyloid hypothesis for Alzheimer’s disease
Abstract
Solanezumab’s failure is a wake-up call to look elsewhere for an answer to dementia Is the amyloid cascade hypothesis of Alzheimer’s disease too big to fail?1 It proposes that brain deposition of β amyloid protein is the critical early event in the pathogenesis of Alzheimer’s disease and has been the centrepiece of dementia research for decades.2 The hypothesis suggests that removing β amyloid will reverse or prevent the clinical expression of dementia. However, in all phase III clinical trials to date, treatments targeting β amyloid have failed to improve cognitive outcomes despite reducing brain β amyloid.3 It is widely argued that these negative trials do not disprove the hypothesis but that treatments should be given decades earlier before β amyloid has “caused” neuronal loss, or that the trials had included people without amyloid deposits.2 The results of a third trial investigating solanezumab (EXPEDITION3), a monoclonal antibody targeting amyloid plaques, were therefore eagerly awaited after the first two trials had negative results but with post hoc indications of potential effects on …Keywords
This publication has 7 references indexed in Scilit:
- Defeating Alzheimer's disease and other dementias: a priority for European science and societyThe Lancet Neurology, 2016
- Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patientsAlzheimer's & Dementia, 2015
- The case for rejecting the amyloid cascade hypothesisNature Neuroscience, 2015
- Geroscience: Linking Aging to Chronic DiseaseCell, 2014
- Alzheimer’s disease drug-development pipeline: few candidates, frequent failuresAlzheimer's Research & Therapy, 2014
- Making Alzheimer's and dementia research fit for populationsThe Lancet, 2012
- Compounding artefacts with uncertainty, and an amyloid cascade hypothesis that is ‘too big to fail’The Journal of Pathology, 2011